Atossa Therapeutics Announces Successful In vitro Testing Results of COVID-19 Drug: AT-H201 Inhibits SARS-CoV-2 Infectivity o...
May 20 2020 - 9:30AM
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage
biopharmaceutical company seeking to discover and develop
innovative medicines in areas of significant unmet medical need
with a current focus on breast cancer and COVID-19, today announced
the successful results from in vitro testing of AT-H201, Atossa’s
proprietary COVID-19 drug candidate. The preliminary study results
show that AT-H201 inhibits SARS-CoV-2 infectivity of VERO cells in
a laboratory culture, which are the standard cell types being used
to study infectivity of the coronavirus. SARS-CoV-2, sometimes
called the coronavirus, is the COVID-19 infectious
agent.
AT-H201 is designed to act as a “chemical vaccine”
by binding to the surface of the coronavirus and inhibiting the
ability of the virus to enter a cell (“viral infectivity”).
Significant findings from the testing include:
- AT-H201 components inhibited SARS-CoV-2 from infecting VERO
cells in a laboratory culture.
- This is the first submicromolar inhibitor of SARS-CoV-2
identified to date in published literature, meaning that a
relatively small amount of the drug is necessary to result in an
anti-viral effect.
- Testing was also performed on remdesivir, an anti-viral
medication being studied by others for use in COVID-19 patients,
and the generic anti-malaria drug hydroxychloroquine, which is also
being studied by others in COVID-19 patients. In these laboratory
tests, the components of AT-H201 were found to be at least
four-times more potent than remdesivir and at least twenty-times
more potent than hydroxychloroquine. Potency was measured by
microscopic examination of the cytopathic effect caused by
SARS-CoV-2 in VERO cells.
“These results support the continued development of AT-H201 for
COVID-19 patients and beginning studies in the clinical setting,”
said Dr. Steven Quay, Atossa’s President and Chief Executive
Officer. “We look forward to reporting progress in clinical
studies.”
The testing was conducted on behalf of Atossa by a leading
academic research institute. Atossa plans to publish a manuscript
of these test results. Successful in vitro tests do not guarantee
similar results from in vivo studies, including in human clinical
trials. Additional safety and efficacy studies must be successfully
completed and regulatory approvals must be obtained before AT-H201
may be commercialized.
About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical
company seeking to discover and develop innovative medicines in
areas of significant unmet medical need with a current focus on
breast cancer and COVID-19. For more information, please visit
www.atossatherapeutics.com.
Forward-Looking Statements
Forward-looking statements in this press release, which Atossa
undertakes no obligation to update, are subject to risks and
uncertainties that may cause actual results to differ materially
from the anticipated or estimated future results, including the
risks and uncertainties associated with any variation between
interim and final clinical results, whether in vitro test results
will also be achieved in in vivo studies, including human clinical
studies, actions by and interactions with the FDA, the outcome or
timing of regulatory approvals needed by Atossa including those
needed to commence human clinical studies of AT-H201, lower than
anticipated rate of patient enrollment, estimated market size of
drugs under development, the safety and efficacy of Atossa’s
products, performance of clinical research organizations and
investigators, obstacles resulting from proprietary rights held by
others such as patent rights, and other risks detailed from time to
time in Atossa’s filings with the Securities and Exchange
Commission, including without limitation its periodic reports on
Form 10-K and 10-Q, each as amended and supplemented from time to
time.
Company Contact: Atossa Therapeutics, Inc. Kyle Guse, CFO and
General Counsel Office: 866 893-4927 kyle.guse@atossainc.com
Investor Relations Contact: Core IROffice:(516)
222-2560ir@atossainc.com
Source: Atossa Therapeutics, Inc.
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Apr 2023 to Apr 2024